MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
9.84
-0.23
-2.24%
Opening 13:12 05/14 EDT
OPEN
10.17
PREV CLOSE
10.06
HIGH
10.22
LOW
9.79
VOLUME
2.74M
TURNOVER
--
52 WEEK HIGH
11.11
52 WEEK LOW
5.34
MARKET CAP
2.06B
P/E (TTM)
-38.0759
1D
5D
1M
3M
1Y
5Y
1D
BioCryst’s Strategic Advancements and Market Potential: A Buy Rating by Serge Belanger
TipRanks · 2h ago
BioCryst's Orladeyo up for FDA review in pediatric HAE patients
Seeking Alpha · 3h ago
BioCryst’s ORLADEYO Receives FDA Priority Review
TipRanks · 5h ago
BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years
Reuters · 5h ago
BioCryst Gets Speedy FDA Review of Pediatric Use of Orladeyo
Dow Jones · 5h ago
BioCryst Announces FDA Acceptance Of Orladeyo's NDA For Hereditary Angioedema Treatment
NASDAQ · 5h ago
BioCryst announces FDA acceptance of NDA for ORLADEYO
TipRanks · 5h ago
BIOCRYST PHARMACEUTICALS: FILED LINE EXTENSION APPLICATION FOR USE OF ORLADEYO ORAL GRANULES IN PATIENTS WITH HAE AGED 2-11 YEARS WITH EMA
Reuters · 6h ago
More
About BCRX
More
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Recently
Symbol
Price
%Change

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.